Daniel Macuga Jr. compensation by year
USANA HEALTH SCIENCES Summary Compensation Table · all 3 fiscal years held| Component | FY2021 | FY2022 | FY2023 |
|---|---|---|---|
| Salary | $474,556 | $488,793 | $490,441 |
| Bonus | $0 | $0 | $0 |
| Stock awards | $571,369 | $588,515 | $588,547 |
| Option awards | $0 | $0 | $0 |
| Non-equity incentive | $206,859 | $72,146 | $61,011 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $10,150 | $10,675 | $11,550 |
| Total | $1,262,934 | $1,160,129 | $1,151,549 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: USANA HEALTH SCIENCES INC DEF 14A filed March 22, 2024, accession 0000896264-24-000119, and prior-year filings. Open the filing on EDGAR.
How this page was built: the USANA HEALTH SCIENCES INC filed document, accession 0000896264-24-000119. Every figure is read from that document and cited to the page and table it appears in. Filed March 22, 2024.
Equity holdings
unvested awards at FY2023 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 10,011 | $536,590 | — |
| RSU | 4,741 | $254,118 | — |
| PSU | 6,123 | $245,221 | — |
| RSU | 3,353 | $179,721 | — |
| RSU | 2,201 | $117,974 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in USANA HEALTH SCIENCES INC's FY2023 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
2 Form 4 lines since the FY2023 proxy (filed March 22, 2024)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2024-05-02 | Sale | — | 3,791 | $47.14 | 0 |
| 2024-05-02 | Sale | — | 3,791 | $47.14 | 0 |
The 2 most recent of 2 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
USANA HEALTH SCIENCES’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| Kevin Guest | Executive Chairman of the Board | $3,911,856 |
| Jim Brown | Chief Executive Officer & President (former) | $2,472,017 |
| G. Douglas Hekking | Chief Financial Officer | $1,469,101 |
| Walter Noot | Chief Operating Officer | $1,417,490 |
| Joshua Foukas | Chief Legal Officer & General Counsel | $1,292,741 |
| Daniel Macuga Jr. · this page | Chief Communications & Marketing Officer | $1,151,549 |
| Brent Neidig | Chief Commercial Officer | $1,045,689 |
The full USANA HEALTH SCIENCES compensation record
free company briefThis page is one person within USANA HEALTH SCIENCES's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the USANA HEALTH SCIENCES proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are USANA HEALTH SCIENCES's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.